coin-img-ETHETH-1.38%coin-img-BTCBTC-1.64%coin-img-SOLSOL-0.43%coin-img-XRPXRP-1.49%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.32%coin-img-DOGEDOGE-2.18%coin-img-TRXTRX+0.06%coin-img-ETHETH-1.38%coin-img-BTCBTC-1.64%coin-img-SOLSOL-0.43%coin-img-XRPXRP-1.49%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.32%coin-img-DOGEDOGE-2.18%coin-img-TRXTRX+0.06%coin-img-ETHETH-1.38%coin-img-BTCBTC-1.64%coin-img-SOLSOL-0.43%coin-img-XRPXRP-1.49%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.32%coin-img-DOGEDOGE-2.18%coin-img-TRXTRX+0.06%coin-img-ETHETH-1.38%coin-img-BTCBTC-1.64%coin-img-SOLSOL-0.43%coin-img-XRPXRP-1.49%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.32%coin-img-DOGEDOGE-2.18%coin-img-TRXTRX+0.06%
user-avatar
GlobeNewswire

Erasca investors urged to seek lead-plaintiff role in ERAS securities class action by Aug. 10, 2026

A U.S. law firm has filed a securities class action against Erasca, Inc. (NASDAQ: ERAS), alleging false and misleading statements about its drug candidate ERAS-0015. The suit covers investors who bought Erasca securities between Jan. 14, 2025 and April 26, 2026. It claims the company relied on improper benchmarking for preclinical data, faced patent-infringement risk, and lacked a scientific basis for optimistic statements, according to the complaint. The case has been filed but has not yet been certified as a class action.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks